Project 2025: Proposals for the Continued Success of Drug Development in Acute Myeloid Leukemia
Year: 2021
Type: article
Abstract: The Food and Drug Administration Oncology Center of Excellence initiated Project 2025 to develop 5-year goals in specific areas of oncology drug development. This meeting, in October 2020, brought together a panel of regulators and academic experts in acute myeloid leukemia (AML) to discuss opportunities to maximize the success that has recently occurred in AML drug development. The panel discussed challenges and opportunities in clinical trial design and novel endpoints, and outlined key considerations for drug development to facilitate continued growth in the field.
Source: Clinical Cancer Research
Authors: Daniel A. Pollyea, John Barrett, Courtney D. DiNardo, Laura C. Michaelis, Gail J. Roboz, Robert Q. Le, Kelly J. Norsworthy, R. Angelo de Claro, Marc R. Theoret, Richard Pazdur
Institutions: University of Colorado Anschutz, University of Colorado Denver, George Washington University, The University of Texas MD Anderson Cancer Center, Medical College of Wisconsin, NewYork–Presbyterian Hospital, Weill Cornell Medicine, United States Food and Drug Administration, Center for Drug Evaluation and Research
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W3214212825
